Surgery is the most common form of the treatment for most<unk> s that have not spread to other parts of the body. Limb-sparing surgery, as opposed to amputation, can now be used to save the limbs of patients in at least 90% of extremity (arm or leg)<unk>  cases. Additional treatments, including chemotherapy, radiation therapy (also called "radiotherapy") and proton therapy, may be administered before surgery (called "neoadjuvant" chemotherapy or radiotherapy) or after surgery (called "adjuvant" chemotherapy or radiotherapy). The use of neoadjuvant or adjuvant chemotherapy and radiotherapy significantly improves the prognosis for many<unk>  patients. Treatment can be a long and arduous process, lasting about a year for many patients. * Liposarcoma treatment consists of surgical resection, with chemotherapy not being used outside of the investigative setting. Adjuvant radiotherapy may also be used after surgical excision for liposarcoma. * Rhabdomyosarcoma is treated with surgery, radiotherapy, or chemotherapy. The majority of rhabdomyosarcoma patients have a 50–85% survival rate. * Osteosarcoma is a tumor of the bone that is treated with surgical resection of as much of the cancer as possible, often along with neoadjuvant chemotherapy. Radiotherapy is a second alternative although not as successful. Expression of receptor B7-H3 provides a promising target for new immunotherapeutic strategies. In childhood<unk> s, the cytotoxic agent cyclophosphamide is widely used and has shown good anti-tumour efficacy. It is believed that higher doses of chemotherapy might improve survival. However, high doses of chemotherapy stop the production of blood cells in the bone marrow and can be harmful. Stem cells collected from people before high‐dose chemotherapy can be transplanted back to the person if the blood cell count gets too low; this is called autologous hematopoietic stem cell transplantation. Research to investigate if using high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation was more favourable than standard‐dose chemotherapy found only one RCT and this did not favour either of the two treatment arms with respect to overall survival. Further evidence is needed through well‐designed clinical trials.
Sarcoma
Angiosarcoma
Soft-tissue sarcoma
Hemangiosarcoma
Xanthoma
Myosarcoma
Epithelioma
Liposarcoma